Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 8/20 | 0.35 |
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | CES2 | O00748 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3688748 | 0.90 | CA14 (0.35) | CA14DGAT1CYP2D6FAAHCES1 | |
| SCHEMBL19216586 | 0.86 | DGAT1 (0.37) | CA14DGAT1CYP2D6MEN1KMT2A | |
| SCHEMBL6206868 | 0.81 | DGAT1 (0.39) | CA14DGAT1CYP2D6MEN1KMT2A | |
| SCHEMBL241533 | 0.80 | DGAT1 (0.46) | CA14DGAT1CYP2D6MEN1KMT2A | |
| SCHEMBL197340 | 0.78 | MGAM (0.48) | FAAHCES1CES2MEN1CYP1A2 | |
| Methyl Alcohol SCHEMBL27995686 | 0.78 | DGAT1 (0.44) | CA14DGAT1CYP2D6MEN1KMT2A | |
| SCHEMBL31692035 | 0.77 | PLOD2 (0.34) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL12203255 | 0.76 | DGAT1 (0.35) | CA14DGAT1CYP2D6MEN1CYP1A2 | |
| SCHEMBL18787715 | 0.76 | DGAT1 (0.40) | CA14DGAT1CYP2D6MEN1KMT2A | |
| SCHEMBL4466465 | 0.75 | PLOD2 (0.39) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110832110-A | Method for producing a metal nanoparticle layer and use thereof in decorative or security elements | 巴斯夫欧洲公司 | 2020-02-21 | — | — | CN | claimed |
| US-20250234865-A1 | Additive Composition for Antifouling Coatings | Arxada, LLC | 2025-07-24 | — | — | US | disclosed |
| EP-4402215-A1 | ADDITIVE COMPOSITION FOR ANTIFOULING COATINGS | Arxada, LLC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11643561-B2 | Process for the preparation of metallic nano-particle layers and their use for decorative or security elements | BASF SE | 2023-05-09 | — | — | US | disclosed |
| US-11643561-B2 | Process for the preparation of metallic nano-particle layers and their use for decorative or security elements | BASF SE | 2023-05-09 | — | — | US | disclosed |
| WO-2023064524-A1 | ADDITIVE COMPOSITION FOR ANTIFOULING COATINGS | Arxada, LLC (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230019988-A1 | Compositions for Antifouling Protection | Arxada Switzerland AG (CH) | 2023-01-19 | — | — | US | disclosed |
| CN-114026181-A | Composition for antifouling protection | 阿尔萨达股份公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200230646-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORATIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020148780-A1 | PROCESS FOR PREPARATION OF 4,4,4- TRIFLUOROBUT-2-EN-1-OL AND INTERMEDIATE THEREOF | SRF LIMITED (IN) | 2020-07-23 | — | — | WO | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3202766-A1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-09 | — | — | EP | disclosed |
| CN-104109077-B | A kind of preparation method of 2,3,3,3-tetrafluoeopropene | JIANG University OF TECHNOLOGY (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-104109077-A | A preparing method of 2,3,3,3-tetrafluoropropene | UNIV ZHEJIANG TECHNOLOGY | 2014-10-22 | — | — | CN | disclosed |
| US-5252603-A | Immunosuppressive analogues and derivatives of succinylacetone | CETUS CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
| US-5216005-A | Treating autoimmune diseases, organ tissue transplants | CETUS CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| US-5173482-A | A dioxoalkyl phosponate or a proline-modified polyoxyethylene glycol derivative; autoimmune diseases; organ transplants; immunoassay | CETUS CORPORATION (US) | 1992-12-22 | — | — | US | disclosed |
| US-4895872-A | TREATING HYPERACTIVE IMMUNE SYSTEMS; AUTOIMMUNE AND GRAFT/HOST DISEASES | CETUS CORPORATION (US) | 1990-01-23 | — | — | US | disclosed |
| WO-1990000049-A2 | IMMUNOSUPPRESSIVE ANALOGUES AND DERIVATIVES OF SUCCINYLACETONE | CETUS CORPORATION (US) | 1990-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | IDH1, IDH3A, IDH3B | CA14 1823/4885DGAT1 2881/4885CYP2D6 1464/4885 |
| US-20250234865-A1 | Additive Composition for Antifouling Coatings | PSPH, PHOSPHO1, CFD | CA14 206/4885DGAT1 182/4885CYP2D6 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.